Medical Oncologist
About 5–10% of breast cancers are hereditary — caused by an inherited change in genes like BRCA1, BRCA2, PALB2 or TP53. If breast cancer runs in your family, knowing your genetic status lets you act early. CION's tumor-board-led hereditary-cancer team in Hyderabad guides you through genetic counselling, testing and a personalised surveillance or risk-reducing plan — with a free first consultation.
Not every breast cancer that appears in a family is inherited. Doctors group breast cancer into three patterns, and the difference matters because it changes how you and your relatives are screened.
Sporadic breast cancer makes up the large majority of cases — roughly 70–80%. It happens by chance as cells age and accumulate damage, with no single inherited gene change driving it. Familial breast cancer (about 15–20%) means more cases appear in a family than expected, often from a mix of shared lifestyle, environment and several low-risk genes — but no single high-risk mutation is found on testing. Hereditary breast cancer (about 5–10%) is different: one specific inherited gene change — in BRCA1, BRCA2, PALB2, TP53 and others — is passed down and strongly raises lifetime risk. This is the group genetic testing is designed to find, because it unlocks early, targeted prevention.
If you are unsure which pattern fits your family, that is exactly what a genetic counselling consultation clarifies — before any test is ordered.
Occurs by chance with cell ageing; no single inherited mutation. Standard screening applies.
Clustered in a family from shared genes and environment, but no high-risk mutation is identified.
A single inherited high-risk gene change (e.g. BRCA1/2, PALB2, TP53) is found and confirmed by testing.
In Indian multi-gene studies of over 1,000 breast cancer patients, BRCA1 and BRCA2 accounted for the majority of pathogenic mutations found — but a meaningful share sat in other genes such as PALB2, TP53, CHEK2 and ATM. That is why a single-gene test is no longer enough: a multi-gene panel finds inherited risk a BRCA-only test would miss. Source: published Indian hereditary breast cancer cohort data; NCCN testing guidance.
Hereditary breast cancer is not only about BRCA. Modern multi-gene panels — the same ones used in Indian studies of over 1,000 patients — test several genes at once because mutations also appear in PALB2, TP53, CHEK2 and ATM. Each gene carries a different level of risk, which is why your result must be interpreted by a specialist, not a home kit. The ranges below are widely cited lifetime estimates; your personal risk depends on your family history and other factors.
A tumour-suppressor gene. Lifetime breast cancer risk is estimated at roughly 55–65% (up to ~72% in some studies), and these cancers are often triple-negative and diagnosed younger. BRCA1 also raises ovarian cancer risk to around 40%. In Indian multi-gene studies, BRCA genes account for the majority of pathogenic mutations found.
The other principal high-risk gene. Lifetime breast cancer risk is estimated at roughly 45–69%, with raised ovarian (~15–20%), prostate and pancreatic cancer risk. BRCA2 also drives most hereditary male breast cancer, with a male lifetime risk of about 5–10%.
Partner And Localizer of BRCA2 — it works alongside BRCA2. Now recognised as a high-risk gene, with an estimated lifetime breast cancer risk of about 40–60%, approaching BRCA levels in families with several affected relatives. It is included on Indian hereditary-cancer panels.
Causes Li-Fraumeni syndrome — a rare but very high-risk condition. Breast cancer risk in women is very high and often very early (before age 35), alongside sarcomas, brain tumours and adrenal cancers. Carriers need specialised, intensive surveillance, usually including breast MRI.
A moderate-risk gene. Lifetime breast cancer risk is estimated at roughly 20–30%, depending on the specific variant and family history. Often managed with enhanced screening rather than surgery, but the decision is individual.
Another moderate-risk gene, with an estimated lifetime breast cancer risk of about 20–30%, and a possible link to pancreatic cancer. Like CHEK2, it usually shifts you into a higher-surveillance pathway tailored at the tumour board.
Genes such as BRCA1 and BRCA2 are tumour-suppressor genes — their normal job is to repair DNA and stop cells growing out of control. When you inherit a faulty copy, that repair system is weaker from birth, so abnormal cells are more likely to slip through over a lifetime. That is why hereditary breast cancers tend to appear younger and why risk is measured as a lifetime figure rather than a here-and-now number.
It is important to read these figures correctly. A 45–85% lifetime risk does not mean cancer is certain, and it is not the same as your risk this year. It means that, without action, the chance accumulates across decades. The reason genetic testing is worth doing is that this risk is highly modifiable — intensive screening catches cancer early, and risk-reducing options can lower the chance substantially. At CION, every result is discussed by our tumour board so the number becomes a clear, personalised plan instead of a frightening statistic.
An inherited faulty copy means DNA-repair defences are reduced from birth, raising lifetime odds.
Hereditary breast cancers often present before 50, so screening starts earlier than usual.
Knowing your status lets you lower risk through surveillance, medication or risk-reducing surgery.
There is no symptom that tells you a cancer is hereditary — the clues are in your age, the tumour type, and your family tree. International guidelines (NCCN, ESMO) and Indian testing criteria flag the following red flags. If one or more apply to you or a close relative, a genetic counselling consultation is worthwhile.
Breast cancer at or before age 50, especially before 40.
Triple-negative breast cancer, particularly diagnosed before age 60.
Bilateral breast cancer or more than one primary breast tumour.
Any breast cancer in a man is a strong indicator for genetic testing.
Two or more close relatives with breast cancer, or relatives with ovarian, pancreatic or prostate cancer on the same side.
A relative already carries a BRCA/PALB2 mutation, or you have Ashkenazi Jewish ancestry.
Talk to our team
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Free first consultation. Confidential, counselling-led genetic guidance at CION Cancer Clinics, Hyderabad. Call us: 1800-202-8726.
If your history fits the red flags, the pathway is structured and unhurried. It begins with genetic counselling — a detailed conversation that maps your family tree and explains what each possible result would mean — before any sample is taken. Testing itself is simple: a blood or saliva sample analysed with a multi-gene panel using next-generation sequencing. Results come back in three forms — a pathogenic (harmful) variant, no variant found, or a Variant of Uncertain Significance (VUS) that needs careful interpretation. Home DNA kits are not enough here: they read only a handful of variants and can miss harmful ones, so testing should be clinical and counselling-led.
A positive result does not mean surgery is the only path. Options are matched to your gene, age and wishes, and reviewed by our tumour board:
Hereditary breast cancer genes are autosomal dominant. In plain terms: if a parent carries a mutation, each child has a 50% chance of inheriting it — sons as well as daughters, because these genes affect more than breast tissue. This is the single most important reason to test. A positive result in one person is a gift of early warning for the whole family.
When a mutation is confirmed, relatives can have cascade testing — a targeted, simpler test that looks only for the family's known variant. Those who test positive can start early surveillance; those who test negative often need only standard screening, which is reassuring and avoids unnecessary worry. CION's counsellors help you decide who to inform and how, and support relatives through their own testing — including children when they reach an appropriate age. It is a family conversation, and we walk that journey with you.
Sons and daughters each have a one-in-two chance of inheriting a parent's mutation.
Relatives get a simpler, targeted test for the family's specific known variant.
Relatives who test negative for the family variant usually need only standard screening.
At CION Cancer Clinics, hereditary risk is handled by a team, not a single doctor. As a woman-headed, tumor-board-led organisation, we built a pathway that is calm, transparent and counselling-first — because a genetic result should guide healing, not fear. Every consultation runs a full 45 minutes, with no rushed decisions and no unnecessary tests.
With 150+ years of combined oncology experience, 17 super-specialist oncologists and 35+ centres across Telangana and AP, we have guided more than 15,000 patients and families — earning a 4.8/5 Google rating across our centres. For breast cancer, CION's outcomes lead the national average. Your first consultation is free.
CION breast cancer 1-year survival: 96.9% vs national average 85.4% (+11.5%). *1-year survival. Source: ICMR / National Cancer Registry Programme (NCRP).
Hear from patients and families who navigated hereditary breast cancer risk with CION's counselling-led pathway.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Talk to our team
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
No. Most breast cancer in families is not truly inherited. About 70–80% of all breast cancers are sporadic (by chance), and another 15–20% are familial — clustered in a family from shared genes and lifestyle but with no single high-risk mutation. Only around 5–10% are hereditary, caused by a specific inherited gene change such as BRCA1, BRCA2 or PALB2. The only way to know which pattern fits your family is a genetic counselling consultation, which reviews your family tree and decides whether a multi-gene test is worthwhile. At CION, this conversation always comes before any test is ordered.
Modern testing uses a multi-gene panel rather than a single gene. The high-risk genes are BRCA1 and BRCA2, plus PALB2 (now recognised as high-risk) and TP53 (which causes Li-Fraumeni syndrome). Moderate-risk genes such as CHEK2 and ATM are also included, along with others on comprehensive Indian panels. Each gene carries a different level of risk, so the same test result means different things depending on which gene is involved. This is exactly why results need a specialist and a genetic counsellor to interpret — and why home DNA kits, which read only a few variants, are not reliable for medical decisions.
It depends on the gene. A BRCA1 mutation carries an estimated lifetime breast cancer risk of roughly 55–65%, and BRCA2 around 45–69%. PALB2 is now considered high-risk too, at about 40–60%. Moderate-risk genes such as CHEK2 and ATM raise lifetime risk to roughly 20–30%. TP53 (Li-Fraumeni) carries a very high, often very early risk. Importantly, these are lifetime figures accumulated over decades, not a chance for this year — and they are not a certainty. Because the risk is modifiable through surveillance and risk-reducing options, knowing your number lets you act early rather than worry.
There is no symptom that proves a cancer is hereditary — the clues are in your age, the tumour type and your family history. Red flags from international (NCCN, ESMO) and Indian guidelines include: breast cancer diagnosed at or before age 50; triple-negative breast cancer before 60; cancer in both breasts or more than one primary tumour; any male breast cancer; two or more close relatives with breast cancer; a family history of ovarian, pancreatic or prostate cancer on the same side; a known mutation in a relative; or Ashkenazi Jewish ancestry. If any of these apply to you, a genetic counselling consultation at CION can clarify whether testing is appropriate.
No. Risk-reducing mastectomy is one option for high-risk genes, but it is always an informed, personal choice — never automatic. Many carriers choose enhanced surveillance instead: earlier and more frequent breast MRI and mammography to catch any cancer at its most treatable stage. Some are suitable for risk-reducing medication. For high-risk genes, risk-reducing surgery can lower breast cancer risk by up to about 90%, but the right path depends on your gene, age, family plans and wishes. At CION, every positive result is reviewed by our tumour board so the decision is unhurried and genuinely yours.
Hereditary breast cancer genes are autosomal dominant, which means if you carry a mutation each of your children has a 50% chance of inheriting it — sons as well as daughters. Your siblings each have a similar chance. When a mutation is confirmed, relatives can have cascade testing: a simpler, targeted test that looks only for your family's known variant. Those who test positive can begin early surveillance, and those who test negative usually need only standard screening, which is reassuring. CION's counsellors help you decide who to inform and support relatives, including children when they reach an appropriate age, through their own testing.
No. Direct-to-consumer home kits typically check only a small handful of the thousands of known harmful variants, so a 'negative' result can be falsely reassuring and miss a mutation that matters. They also do not provide the genetic counselling needed to interpret results correctly or to plan next steps. For medical decisions, testing should be clinical and counselling-led, using a comprehensive multi-gene panel analysed by an accredited laboratory. At CION, genetic counselling comes before testing and after results, so your decisions are based on a complete and correctly interpreted picture.
Start with a free first consultation. You can book online or call CION at 1800-202-8726. Your first appointment is a 45-minute genetic counselling conversation in which a specialist reviews your personal and family history and explains whether a multi-gene test is right for you and what each result would mean — with no pressure and no unnecessary tests. If you proceed, testing is a simple blood or saliva sample. Every result is then reviewed by our tumor board, and we build a personalised surveillance or risk-reducing plan and support cascade testing for your family. We walk this journey with you.
Browse our complete guide to breast cancer — types, symptoms, tests and treatments. Tap any topic to read more.